ID   A431/TPT
AC   CVCL_4V41
DR   cancercelllines; CVCL_4V41
DR   Wikidata; Q54606919
RX   PubMed=19765546;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:63632; Topotecan.
CC   Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Skin, epidermis; UBERON=UBERON_0001003.
DI   NCIt; C4819; Skin squamous cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0037 ! A-431
SX   Female
AG   85Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 05-10-23; Version: 12
//
RX   PubMed=19765546; DOI=10.1016/j.bcp.2009.09.012;
RA   Zuco V., Supino R., Favini E., Tortoreto M., Cincinelli R.,
RA   Croce A.C., Bucci F., Pisano C., Zunino F.;
RT   "Efficacy of ST1968 (namitecan) on a topotecan-resistant squamous cell
RT   carcinoma.";
RL   Biochem. Pharmacol. 79:535-541(2010).
//